Gene-edited crops pioneer Calyxt crashes, giving the lie to deregulation claims
By Jonathan Matthews and Claire Robinson,
GMWatch
| 10. 02. 2022
Kelly Sikkema for Unsplash
As governments around the world are lobbied by industry with claims gene editing can deliver rapid solutions to our food and farming problems — they just need deregulation, the company that pioneered gene-edited crops in the lax regulatory environment of the US is considering selling its assets amid plummeting revenues and share prices.
Calyxt was the first to market gene-edited soybeans in 2019. The beans are genetically engineered to produce high oleic oil. You might think anyone wanting high oleic oils could just buy olive oil but Calyxt was primarily targeting the processed foods markets by promoting its oil as a healthier alternative to commodity soybean oils that produce trans fats when cooked at high temperatures, though no research directly showed health benefits.
Calyxt was also reported to have other “consumer-focused” gene-edited foods in the pipeline, like high fibre wheat and reduced browning potatoes.
Rapidly developing disruptive technology
The company told investors that as a gene editing pioneer accelerating product development, “this is an exciting time for Calyxt and a rapidly developing disruptive plant-based technology story”...
Related Articles
By Alondra Nelson, Science | 09.11.2025
In the United States, the summer of 2025 will be remembered as artificial intelligence’s (AI’s) cruel summer—a season when the unheeded risks and dangers of AI became undeniably clear. Recent months have made visible the stakes of the unchecked use...
By Emma McDonald Kennedy
| 09.25.2025
In the leadup to the 2024 election, Donald Trump repeatedly promised to make IVF more accessible. He made the commitment central to his campaign, even referring to himself as the “father of IVF.” In his first month in office, Trump issued an executive order promising to expand IVF access. The order set a 90-day deadline for policy recommendations for “lowering costs and reducing barriers to IVF,” although it didn’t make any substantive reproductive healthcare policy changes.
The response to the...
Sir Francis Galton, 1890s, by Eveleen Myers (née Tennant)
npg.org
Public Domain via Wikipedia
As has been discussed in recent issues of Biopolitical Times (1, 2), there are, increasingly, companies that claim to be selling parents better babies by selecting the “best” embryos. These services don’t come cheap – think $50,000, or even more, for embryo testing, plus perhaps as much again for IVF and concomitant services. To most of us, that is extremely expensive...
By Johana Bhuiyan, The Guardian | 09.23.2025
In March 2021, a 25-year-old US citizen was traveling through Chicago’s Midway airport when they were stopped by US border patrol agents. Though charged with no crime, the 25-year-old was subjected to a cheek swab to collect their DNA, which...